Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: abuse-deterrent oral hydrocodone controlled-release - Assertio Therapeutics/Shionogi

Next Previous
Drug Profile

Research programme: abuse-deterrent oral hydrocodone controlled-release - Assertio Therapeutics/Shionogi

Alternative Names: AD Combination hydrocodone; AD ER hydrocodone; Hydrocodone controlled release - Assertio Therapeutics/Shionogi

Latest Information Update: 08 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Egalet
  • Developer Zyla Life Sciences
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 20 May 2020 Assertio Therapeutics has been merged with Zyla Life Sciences to form Assertio Therapeutics
  • 28 Dec 2017 No recent reports of development identified for preclinical development in Pain in Japan (PO, Controlled release)
  • 20 Dec 2017 Research programme: abuse-deterrent oral hydrocodone controlled-release - Egalet/Shionogi is available for licensing as of 20 Dec 2017. http://egalet.com/

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top